You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186.HK):授予阿斯利康博優諾®在中國大陸特定縣域市場獨家推廣權
格隆匯 05-26 22:56

格隆匯5月26日丨綠葉製藥(02186.HK)發佈公吿,集團附屬公司博安生物與阿斯利康中國(“阿斯利康”)已簽署《獨家推廣協議》。博安生物授予阿斯利康博優®(“LY01008”,貝伐珠單抗注射液)在中國21個省市及自治區縣域市場的獨家推廣權。此次合作,博安生物將與阿斯利康緊密攜手,充分發揮雙方優勢,鞏固和拓展博優®在中國的業務和市場覆蓋,推動該產品進一步惠及更多患者人羣。

根據披露,博優諾®(貝伐珠單抗注射液)是由博安生物自主開發的生物抗體藥物。該產品於近期獲得中國國家藥品監督管理局的上市批准,用於治療晚期、轉移性或複發性非小細胞肺癌和轉移性結直腸癌。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account